Talphera, Inc. Common Stock (TLPH) Stock Price

TLPHStock

$1.20+119.90%52W

Market Cap$62.29M

P/E—

PEG Ratio—

Div yield—

Beta0.71

TLPH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)24.33%

Price vs S&P 500 (4W)-11.32%

VGM Score72.07

Book Value / Share (Quarterly)$0.37

P/TBV (Annual)6.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-74.90%

Cash Flow / Share (Quarterly)$-19.92

Price vs S&P 500 (YTD)-7.56%

Gross Margin (TTM)152.49%

Net Profit Margin (TTM)-0.51%

EPS (TTM)$-0.30

10-Day Avg Trading Volume0.25M

EPS Excl Extra (TTM)$-0.30

Revenue Growth (5Y)-65.12%

EPS (Annual)$-0.34

Dividend / Share (Annual)$23.88

ROI (Annual)-83.89%

Gross Margin (Annual)614639.02%

Net Profit Margin (5Y Avg)-10630.61%

Cash / Share (Quarterly)$0.42

ROA (Last FY)-48.08%

Revenue Growth TTM (YoY)5127677.78%

EBITD / Share (TTM)$13.82

ROE (5Y Avg)-250.86%

Operating Margin (TTM)-0.46%

Cash Flow / Share (Annual)$-0.23

P/B Ratio3.40x

P/B Ratio (Quarterly)2.02x

Net Income / Employee (Annual)$-1,190,800

Net Interest Coverage (TTM)61.47x

ROA (TTM)-53.22%

EV / EBITDA (TTM)0.08x

EPS Incl Extra (Annual)$-0.34

Current Ratio (Annual)5.49x

Quick Ratio (Quarterly)5.24x

3-Month Avg Trading Volume0.27M

52-Week Price Return119.90%

Revenue / Employee (TTM)$115,375,000

Tangible BV / Share (Quarterly)$0.19

P/S Ratio (Annual)2243.07x

Asset Turnover (Annual)0.00x

52-Week High$1.57

Operating Margin (5Y Avg)-10970.44%

EPS Excl Extra (Annual)$-0.34

26-Week Price Return36.26%

Quick Ratio (Annual)5.35x

13-Week Price Return46.06%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.30x

Enterprise Value$58.98M

Revenue / Share Growth (5Y)-77.71%

Asset Turnover (TTM)60.54x

Revenue / Employee (Annual)$2,300

Inventory Turnover (Annual)77.48x

Pretax Margin (Annual)-51296.43%

Cash / Share (Annual)$0.41

3-Month Return Std Dev72.07%

Gross Margin (5Y Avg)122870.11%

Net Income / Employee (TTM)$-1,187,800

ROE (Last FY)-83.89%

Net Interest Coverage (Annual)-12.01x

EPS Basic Excl Extra (Annual)$-0.34

Receivables Turnover (TTM)1.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.30

Receivables Turnover (Annual)0.00x

ROI (TTM)-92.98%

P/S Ratio (TTM)0.05x

Pretax Margin (5Y Avg)-10433.42%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.17

Price vs S&P 500 (52W)101.34%

Year-to-Date Return5.26%

5-Day Price Return0.84%

EPS Normalized (Annual)$-0.34

ROA (5Y Avg)-30.82%

Net Profit Margin (Annual)-51035.71%

Month-to-Date Return-6.25%

EBITD / Share (Annual)$-0.32

Operating Margin (Annual)-48157.14%

LT Debt / Equity (Annual)173.40x

ROI (5Y Avg)-97.23%

LT Debt / Equity (Quarterly)121.75x

EPS Basic Excl Extra (TTM)$-0.30

P/TBV (Quarterly)3.87x

P/B Ratio (Annual)3.12x

Inventory Turnover (TTM)2.78x

Pretax Margin (TTM)-0.51%

Book Value / Share (Annual)$0.35

Price vs S&P 500 (13W)44.10%

Beta0.71x

Revenue / Share (TTM)$19.83

ROE (TTM)-92.98%

52-Week Low$0.50

vGradeA

gGradeC

mGradeA

vgmGradeB

TLPH Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.07	-$0.05	+23.54%(+$0.02)
Q1 2026	May 13, 2026	-$0.08	-$0.05	+36.13%(+$0.03)
Q4 2025	Mar 23, 2026	-$0.07	-$0.06	+20.00%(+$0.02)
Q3 2025	Nov 12, 2025	-$0.13	-$0.13	-6.72%(-$0.01)
Q2 2025	Aug 14, 2025	-$0.12	-$0.10	+9.13%(+$0.01)

TLPH Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.11

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
TLPHTalphera, Inc. Common Stock	A	C	A	$1.20
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Talphera, Inc. Common Stock

Talphera Inc. is a pharmaceutical company developing therapies for medically supervised clinical settings. Its pipeline centers on nafamostat product candidates, including Niyad and LTX-608, with a focus on pre-filled syringe formulations to optimize drug delivery.